Maplight Therapeutics (NASDAQ:MPLT) Releases Earnings Results, Misses Estimates By $1.42 EPS

Maplight Therapeutics (NASDAQ:MPLT) released its quarterly earnings data on Thursday. The company reported ($2.47) EPS for the quarter, missing the consensus estimate of ($1.05) by ($1.42), Zacks reports.

Maplight Therapeutics Price Performance

Shares of NASDAQ:MPLT traded down $0.96 during trading hours on Friday, hitting $18.27. The company’s stock had a trading volume of 24,050 shares, compared to its average volume of 191,140. The company’s fifty day moving average is $17.83. Maplight Therapeutics has a 52 week low of $12.24 and a 52 week high of $21.55. The firm has a market capitalization of $828.91 million and a P/E ratio of -0.50.

Analyst Upgrades and Downgrades

MPLT has been the subject of a number of recent research reports. Canaccord Genuity Group began coverage on Maplight Therapeutics in a report on Thursday, March 19th. They issued a “buy” rating and a $35.00 target price for the company. Weiss Ratings started coverage on shares of Maplight Therapeutics in a research note on Thursday, January 22nd. They set a “sell (e)” rating for the company. Finally, Wall Street Zen downgraded shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Maplight Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $31.80.

Insider Activity at Maplight Therapeutics

In other Maplight Therapeutics news, Director George Pavlov acquired 10,658 shares of Maplight Therapeutics stock in a transaction that occurred on Wednesday, February 18th. The stock was bought at an average price of $17.48 per share, with a total value of $186,301.84. Following the completion of the purchase, the director directly owned 10,658 shares of the company’s stock, valued at approximately $186,301.84. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Timothy John Garnett bought 14,124 shares of the stock in a transaction on Tuesday, February 10th. The shares were bought at an average price of $17.89 per share, with a total value of $252,678.36. Following the acquisition, the director owned 14,124 shares of the company’s stock, valued at $252,678.36. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have acquired 39,124 shares of company stock valued at $693,846 and have sold 74,612 shares valued at $1,368,065.

Institutional Investors Weigh In On Maplight Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Police & Firemen s Retirement System of New Jersey bought a new position in Maplight Therapeutics in the fourth quarter worth about $70,000. New York State Common Retirement Fund bought a new stake in shares of Maplight Therapeutics in the 4th quarter valued at about $93,000. MetLife Investment Management LLC bought a new stake in shares of Maplight Therapeutics in the 4th quarter valued at about $172,000. Walleye Capital LLC purchased a new position in shares of Maplight Therapeutics in the 4th quarter worth approximately $205,000. Finally, Deutsche Bank AG purchased a new position in shares of Maplight Therapeutics in the 4th quarter worth approximately $210,000.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.